ITUB20160828A1 - Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro - Google Patents

Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro

Info

Publication number
ITUB20160828A1
ITUB20160828A1 ITUB2016A000828A ITUB20160828A ITUB20160828A1 IT UB20160828 A1 ITUB20160828 A1 IT UB20160828A1 IT UB2016A000828 A ITUB2016A000828 A IT UB2016A000828A IT UB20160828 A ITUB20160828 A IT UB20160828A IT UB20160828 A1 ITUB20160828 A1 IT UB20160828A1
Authority
IT
Italy
Prior art keywords
estrogens
diet
effectiveness
enhance
cancer therapy
Prior art date
Application number
ITUB2016A000828A
Other languages
English (en)
Inventor
Alessio Nencioni
Alberto Ballestrero
Patrizio Odetti
Fiammetta Monacelli
Irene Caffa
Valter Longo
Original Assignee
Univ Degli Studi Genova
L Nutra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Genova, L Nutra Inc filed Critical Univ Degli Studi Genova
Priority to ITUB2016A000828A priority Critical patent/ITUB20160828A1/it
Priority to CN201780012121.XA priority patent/CN109069451A/zh
Priority to EP17708981.0A priority patent/EP3416632B1/en
Priority to BR112018016820-3A priority patent/BR112018016820A2/pt
Priority to PCT/EP2017/053209 priority patent/WO2017140641A1/en
Priority to RU2018129357A priority patent/RU2018129357A/ru
Priority to AU2017219830A priority patent/AU2017219830A1/en
Priority to US16/075,187 priority patent/US11963941B2/en
Priority to CA3014717A priority patent/CA3014717C/en
Priority to MX2018009949A priority patent/MX2018009949A/es
Priority to JP2018544045A priority patent/JP7071272B2/ja
Priority to ES17708981T priority patent/ES2922284T3/es
Priority to KR1020187026865A priority patent/KR20190003469A/ko
Publication of ITUB20160828A1 publication Critical patent/ITUB20160828A1/it
Priority to ZA201805418A priority patent/ZA201805418B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITUB2016A000828A 2016-02-18 2016-02-18 Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro ITUB20160828A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ITUB2016A000828A ITUB20160828A1 (it) 2016-02-18 2016-02-18 Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
US16/075,187 US11963941B2 (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer
CA3014717A CA3014717C (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy
BR112018016820-3A BR112018016820A2 (pt) 2016-02-18 2017-02-14 uso de uma dieta simulando jejum para aumentar a eficácia dos antiestrogênios na terapia contra o câncer
PCT/EP2017/053209 WO2017140641A1 (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy
RU2018129357A RU2018129357A (ru) 2016-02-18 2017-02-14 Применение имитирующей ограничение питания диеты для повышения эффективности антиэстрогенов при терапии рака
AU2017219830A AU2017219830A1 (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy
CN201780012121.XA CN109069451A (zh) 2016-02-18 2017-02-14 使用禁食模仿饮食来增强抗雌激素在癌症治疗中的疗效
EP17708981.0A EP3416632B1 (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy
MX2018009949A MX2018009949A (es) 2016-02-18 2017-02-14 Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer.
JP2018544045A JP7071272B2 (ja) 2016-02-18 2017-02-14 がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
ES17708981T ES2922284T3 (es) 2016-02-18 2017-02-14 Uso de una dieta que simula el ayuno para mejorar la eficacia de los antiestrógenos en terapia contra el cáncer
KR1020187026865A KR20190003469A (ko) 2016-02-18 2017-02-14 암 치료에서 항에스트로겐의 효능을 강화하기 위한 단식 모방 식단의 사용
ZA201805418A ZA201805418B (en) 2016-02-18 2018-08-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000828A ITUB20160828A1 (it) 2016-02-18 2016-02-18 Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro

Publications (1)

Publication Number Publication Date
ITUB20160828A1 true ITUB20160828A1 (it) 2017-08-18

Family

ID=55948993

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A000828A ITUB20160828A1 (it) 2016-02-18 2016-02-18 Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro

Country Status (14)

Country Link
US (1) US11963941B2 (it)
EP (1) EP3416632B1 (it)
JP (1) JP7071272B2 (it)
KR (1) KR20190003469A (it)
CN (1) CN109069451A (it)
AU (1) AU2017219830A1 (it)
BR (1) BR112018016820A2 (it)
CA (1) CA3014717C (it)
ES (1) ES2922284T3 (it)
IT (1) ITUB20160828A1 (it)
MX (1) MX2018009949A (it)
RU (1) RU2018129357A (it)
WO (1) WO2017140641A1 (it)
ZA (1) ZA201805418B (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018138090A1 (en) 2017-01-26 2018-08-02 Università Degli Studi Di Genova Diet composition for the prevention and/or the treatment of endometrial hyperplasia

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
IT202000008710A1 (it) 2020-04-23 2021-10-23 Ifom Fondazione St Firc Di Oncologia Molecolare Combinazione terapeutica per il trattamento del cancro della mammella
WO2024108336A1 (zh) * 2022-11-21 2024-05-30 中国科学院深圳先进技术研究院 抑制肿瘤细胞生长的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427353T1 (de) * 1997-02-10 2009-04-15 Genentech Inc Heregulin varianten
JP2014508782A (ja) 2011-03-11 2014-04-10 メリマック ファーマシューティカルズ インコーポレーティッド ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALESSANDRO LAVIANO ET AL: "Toxicity in Chemotherapy - When Less Is More", vol. 366, no. 24, 14 June 2012 (2012-06-14), pages 2319 - 2320, XP008172000, ISSN: 0028-4793, Retrieved from the Internet <URL:http://www.nejm.org/doi/full/10.1056/NEJMcibr1202395> [retrieved on 20161007], DOI: 10.1056/NEJMCIBR1202395 *
CHANGHAN LEE ET AL: "Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC, vol. 4, no. 124-127, 7 March 2012 (2012-03-07), pages 74 - 83, XP008171996, ISSN: 1946-6234, [retrieved on 20120208], DOI: 10.1126/SCITRANSLMED.3003293 *
FERNANDO M SAFDIE ET AL: "Fasting and cancer treatment in humans: A case series report", AGING, IMPACT JOURNALS LLC, US, vol. 1, no. 12, 1 December 2009 (2009-12-01), pages 988 - 1007, XP002729596, ISSN: 1945-4589, [retrieved on 20091231] *
IRENE CAFFA ET AL.: "Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition", ONCOTARGET, vol. 6, no. 14, 18 March 2015 (2015-03-18), pages 11820 - 11832, XP055308680, ISSN: 1949-2553, DOI: 10.18632/oncotarget.3689 *
K. CHEN ET AL: "Caloric Restriction Mimetic 2-Deoxyglucose Antagonizes Doxorubicin-induced Cardiomyocyte Death by Multiple Mechanisms", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 25, 24 June 2011 (2011-06-24), US, pages 21993 - 22006, XP055308613, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.225805 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018138090A1 (en) 2017-01-26 2018-08-02 Università Degli Studi Di Genova Diet composition for the prevention and/or the treatment of endometrial hyperplasia

Also Published As

Publication number Publication date
US20190038591A1 (en) 2019-02-07
CA3014717A1 (en) 2017-08-24
KR20190003469A (ko) 2019-01-09
RU2018129357A3 (it) 2020-05-28
AU2017219830A1 (en) 2018-08-30
CA3014717C (en) 2024-06-04
WO2017140641A1 (en) 2017-08-24
EP3416632B1 (en) 2022-04-13
ZA201805418B (en) 2019-11-27
US11963941B2 (en) 2024-04-23
JP2019505555A (ja) 2019-02-28
CN109069451A (zh) 2018-12-21
EP3416632A1 (en) 2018-12-26
RU2018129357A (ru) 2020-03-18
ES2922284T3 (es) 2022-09-12
JP7071272B2 (ja) 2022-05-18
MX2018009949A (es) 2019-03-06
BR112018016820A2 (pt) 2018-12-26

Similar Documents

Publication Publication Date Title
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
PL3943093T3 (pl) Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
RS66458B1 (sr) Kdm1a inhibitor i njegova primena u terapiji
IL260684B (en) Treatment for modulating gut microbiota
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
PL3091919T3 (pl) Odstępy między zabiegiami do stosowania komopozycji zawierających materiały pochłaniające energię do zastosowań dermatologicznych
HUE062714T2 (hu) SGLT2 inhibitorok kutyafélék anyagcserezavarainak kezelésére
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
SG10201912376VA (en) Benzenesulfonamide compounds and their use as therapeutic agents
EP2976070A4 (en) INFLAMMATORY SYNERGISTIC ASTAXANTHINE COMBINATIONS
DK3606926T3 (da) Heteroaromatiske forbindelser anvendelige i terapi
SI2991507T1 (sl) Uporaba sestavka, ki vsebuje ribje olje in sok za zdravljenje raka in po zdravljenju raka
IL268728A (en) Formulations of cannabinoids for the treatment of acne
MA41453A (fr) Encapsulation d&#39;agents actifs très puissants
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
ZA201906473B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
ITUB20160828A1 (it) Utilizzo di una dieta che mima il digiuno per potenziare l&#39;efficacia di antiestrogeni nella terapia del cancro
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
EP3359138C0 (en) Dietary supplementation to achieve oxy-redox homeostasis and epigenetic stability
HUE066098T2 (hu) Ozonizált olajat tartalmazó készítmény használata daganat kezelésében
PL3411029T3 (pl) Sól bursztynianowa cytyzyny i jej zastosowanie
EP3337784A4 (en) USE OF UREIDOMUSTIN (BO-1055) IN CANCER TREATMENT
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra